Scientists test eczema drug delivery in healthy volunteers

NCT ID NCT06268860

Summary

This study aimed to see if a potential eczema medication, rocatinlimab, is absorbed the same way by the body when given from a traditional glass vial versus a newer, ready-to-use prefilled syringe. It involved 240 healthy adults who received a single injection. The main goal was to compare drug levels in the blood between the two delivery methods to ensure they work equally well.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Fortrea Clinical Research Unit - Dallas

    Dallas, Texas, 75247-4903, United States

  • Fortrea Clinical Research Unit - Daytona Beach

    Daytona Beach, Florida, 32117-5116, United States

  • Fortrea Clinical Research Unit Inc. - Madison

    Madison, Wisconsin, 53704-2526, United States

  • Fortrea Clinical Research Unit Limited - Leeds

    Leeds, LDS, LS2 9LH, United Kingdom

Conditions

Explore the condition pages connected to this study.